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1. Introduction  
In the chapter, we hereby provide a brief review about RNA interference (RNAi) and 
elucidate its therapeutic applications. The enzymatic synthesis of double-stranded RNA in 
vitro will be discussed. We also describe how to design and select short interfering RNA 
(siRNA) sequences. In addition, we also introduce a DNA-directed RNAi (ddRNAi) system, 
which is designed for the generation of small hairpin RNAs in mammalian cells and is an 
efficient approach to allow fast and easy expression of hairpin oligonucleotides for 
therapeutic purpose. Moreover, various strategies for delivery of siRNA to target cells are 
discussed in this chapter. Under the consideration of distinct need of different diseases, use 
of transient or stable transfection onto living organism will be introduced. Finally, we will 
discuss the application of RNAi in clinical or preclinical trial. Some ongoing therapeutic 
models, efficacy or limitation for RNAi will be demonstrated and clarified.  
1.1 Overview and mechanism about RNAi 
Andrew Fire and Craig Mello published their break-through study on the mechanism of 
RNA interference in Nature in 1998 (Fire et al., 1998). RNA interference (RNAi) is a 
phenomenon in which double-stranded RNA (dsRNA) suppresses expression of a target 
protein by stimulating the specific degradation of the target mRNA (Fuchs et al. 2004). RNAi 
has been used to study loss of function for a variety of genes in several organisms including 
various plants, Caenorhabditis elegans and Drosophila, and permits loss-of-function genetic 
screens and rapid tests for genetic interactions in mammalian cells (Hannon, 2002; Williams 
et al., 2003). RNAi is generated by a multistep process (Figure 1). First of all, intracellular 
dsRNA is recognized by an RNase III (designated as “Dicer” in Drosophila) and cleaved 
into siRNAs of 21–23 nucleotides (Hammond et al. 2000). These siRNAs are then integrated 
in a complex (designated as “RISC”, RNA-induced silencing complex). Each siRNA in RISC 
is specific and targeting to certain sequences of mRNAs, which is homologous to the 
integral siRNA followed by completely degradation of targeted mRNA. (Hammond et al., 
2000; Bernstein et al., 2001). Actually, the target mRNA is cleaved in the center of the 
sequence complementary to the siRNA (Elbashir et al., 2001c). As a result, rapid degradation 
of the target mRNA and decreased protein expression was observed.  
It is well-known that proteins are responsible for the physical and dynamic properties of a 
living cell, and defects in their function or regulation contribute to many diseases. In fact, 
the majority of drugs used at the present time are actually designed to inactive proteins. 
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Thus, gene therapy using RNAi should be effective in ablating protein function since mRNA 
is the template for the translation of multiple proteins. Much of the interest in RNAi is based 
on the fact that the RNAi mechanism operates upstream of protein production by 
eliminating the mRNAs coding for such proteins. Thus, scientists are eager to finds 
solutions for treating diseases of all kinds and sorts by using RNAi.  
 
 
Fig. 1. Simplified schematic diagram of the proposed RNA interference mechanism.  dsRNA 
processing proteins (RNase III-like enzymes) bind to and cleave dsRNA into siRNA. The 
siRNA forms a multicomponent nuclease complex, the RNA-induced silencing complex 
(RISC). The target mRNA recognized by RISC is cleaved in the center of the region 
complementary to the siRNA and quickly degraded. 
1.2 siRNA design and optimization 
Selecting an optimal target sequence is essential to the success of RNA interference. Since it 
is not possible to predict the optimal siRNA sequence for a given target, many siRNAs are 
usually required to be screened for optimal effects. Suggestions for the determination of 
sequences of siRNAs are usually being modified upon as knowledge of the RNAi continues 
to expand. The general recommendations are as follows: siRNA target sequences should be 
specific to the gene of interest and have GC content with about 20~50 percents (Henshel et 
al. 2004). According to Ui-Tei et al. (2004) and Elbashir et al., 2001a, siRNAs satisfying the 
following “RNAi target selection rules” are capable of effective gene silencing in 
mammalian cells: (1) Targeted regions on the cDNA sequence of a targeted gene should be 
located 50-100 nt downstream of the start codon (ATG). (2)Search for sequence motif 
AA(N19)TT or NA(N21), or NAR(N17)YNN, where N is any nucleotide, R is purine (A, G) 
and Y is pyrimidine (C, U). (3)Avoid targeting introns, since RNAi only works in the 
cytoplasm and not within the nucleus. (4)Avoid sequences with > 50% G+C content. 
(5)Avoid stretches of 4 or more nucleotide repeats. (6)Avoid 5URT and 3UTR, although 
siRNAs targeting UTRs have successfully induced gene inhibition.  
Designing effective siRNAs is essential for effective RNAi knockdown. In addition to 
choosing the optimal sequence, other essential factors that affect the efficacy of siRNA 
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should be as well considered. Once a siRNA sequence is selected using the above algorithm 
of choice, it is important to perform homology examination against all the other genes from 
the organism of your study. In addition, the homology test should be able to identify short 
regions of sequence identity since any siRNA displaying homology with the potential to 
cause mis-targeted effects should be excluded. Despite so many advances in siRNA design 
platforms showing highly likely to be functional, the only way to make sure if designed 
siRNA have the silencing effects in target gene is to validate in an actual experiment.  
1.3 Enzymatic synthesis of siRNA 
Several methods to generate siRNA have been developed. These include the preparation of 
siRNA mixtures using RNase III or Dicer enzymes to digest longer double-strand RNAs 
(dsRNAs) (Andrew et al., 2005; Myers et al., 2003). The short RNAs generated as a result of 
these digestions have been demonstrated to be efficient in RNAi study. siRNA synthesis in 
vitro provides an alternative approach instead of using  the potentially expensive chemical 
synthesis of RNA. Take our study for example, which is published in Journal of Cellular 
Biochemistry (Yang et al., 2007). To analysis the effects of CD36 in renal tubule cells, CD36 
siRNA was designed and synthesized. CD36 is an 88-kD integral-membrane glycoprotein 
that is present on renal tubular; however little is known about its actual biological function. 
We use LLC-PK1 cells to mimic proximal tubule cells. Cells were cultured in 10% fetal calf 
serum supplemented medium for 1 day. The cells were then transfected by 100 nM of 
synthetic CD36 siRNA (sense sequence: CUAAGUUGCUGAGACAAGGdTdT, anti-sense: 
CCUUGUCUCAGCAACUUAGdTdT), which was purchased from commercial biotech 
company. To make sure the silencing effects come from the siRNA introduced, scientists are 
required to make proper control experiments. Usually, we can design reverse sequence for a 
negative control for siRNA study. For example, we designed the reverse control for CD36 
siRNA with sequence as following. Sense sequence is 5’-
dTdTGGAACAGAGUCGUUGAAUC-3’ and anti-sense sequence is 5’-
dTdTGAUUCAACGACUCUGUUCC-3’. Transfecting procedure was performed according 
to manufacturer’s instructions. Cells were mixed with siRNA complex for 24 h and cultured 
in serum-free medium for 36 h. These results were shown in Figure 2. 
1.4 DNA-directed RNAi 
DNA-directed RNA interference (so called “ddRNAi”) involves the introduction of DNA 
templates in cytoplasma and generation of siRNA in vivo. ddRNAi is dependent on RNA 
polymerase III for the production of siRNA which can silence specific gene of interest with 
the sequence related to that of siRNA (Brummelkamp et al. 2002; Novarino et al. 
2004).Target sequences of si/shRNA can be generated by using PCR followed by cloning 
into selected vectors (Yu et al., 2002). Take pSUPER RNAi System for example, the pSUPER 
RNAi System (OligoEngine inc) can generates long-term silencing phenotypes in 
mammalian cell lines by vector system, along with a pair of oligo sequences specific to the 
target sequences that are ligated into the vector, to produce dsRNA and to provoke 
persistent synthesis of siRNA in cytoplasma as shown in Figure 3.  
Vector-based RNA silencing strategy provides a way to induce stable, long-term inhibition 
of gene of interest by generating siRNAs in vivo.  After specific gene silencing, the 
biochemical change in transfected cells can facilitate scientists to study the role of specific 
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Fig. 2. CD36 mRNA is suppressed in LLC-PK1 using CD36 siRNA. CD36 mRNA was 
determined by quantitative real-time PCR in LLC-PK1 cell treated with CD36 siRNA (0, 25, 
50, 100 nM) for 24 h following maintenance of cells in complete medium for 36 h. Bars 
represent mean +/- SEM of three experiments. It is evident that CD36 siRNA is a suitable 
approach applied in CD36 gene silencing. (Adapted from Yang et al., 2007 ) 
 
 
Fig. 3. (A) Demonstrating the sequence (sense strand) and its complement sequence 
(antisense strand) in the duplex form, with 3’ UU overhang. (B) showing the same sequences 
along with hairpin loop. The loop is ready to be degraded by Dicer enzyme following RNA 
transcription. (C) Demonstrating the forward and reverse oligos in relative orientation. 
(Adapted from http://www.oligoengine.com/) 
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gene or protein. On the vectors, markers, such as puromycin or neomycin can be performed 
for long-term suppression of genes of interest. Usually, the silencing time period for 
synthetic siRNAs is between 48–72 hours. Thus, synthetic siRNAs is suitable for transient 
silencing purpose. However, vector-based RNA silencing can induce stable and long-term 
silencing of target gene. Furthermore, to obtain a successful ddRNAi, several parameters 
should be noted. First, well prepare the vectors containing full-length shRNA or siRNA 
sequences. Avoid contaminating endotoxin carried from prokaryotes host. Second, make 
sure of a successful delivery of those vectors into cells and induction of the expression of 
shRNA constructs. Third, properly select and clone siRNA target sequences into expression 
vectors. This sequence consists of two inverted repeats separated by a short spacer sequence 
(loop sequence). After transfection and transcription by RNA polymerase, the inverted 
repeats anneal and form a hairpin structure, which is then cleaved by Dicer to form siRNA. 
Taken together, DNA-Directed RNAi strategies provide another method for quickly and 
easily screening various targets (Yeager et al., 2005).  
2. Therapeutic delivery of RNAi 
There have been several reports on gene expression can be silenced by the targeted 
destruction of specific mRNA molecules in a highly conserved process known as RNAi. It is 
a form of post-transcriptional gene silencing that has been described in a number of plant, 
nematode, protozoan, and invertebrate species. In the recent years, RNAi has emerged as a 
major regulatory mechanism in eukaryotic gene expression. Also, RNAi is a powerful tool to 
silence gene expression in a sequence-specific manner and has the potential to treat diseases 
(ex. cancer therapeutics or in tissue regeneration) which can be corrected by the decreased 
expression of specific proteins (Izquierdo, 2005). A single strand of exogenously introduced 
double-stranded small interfering RNA (siRNA; 20-30 nucleotides) guides an RNA-inducing 
silencing protein complex to degrade the mRNA with the matching sequence; thus, 
translation into the target proteins is silenced (Elbashir et al., 2001b; Hannon & Rossi , 2004; 
Novina & Sharp, 2004). Theoretically, siRNA can interfere with the translation of almost any 
mRNA, as long as the mRNA has a distinctive sequence, whereas the targets of traditional 
drugs are limited by types of cellular receptors and enzymes (de Fougerolles et al., 2007). In 
designing a particular RNAi, it is important to identify the sense/antisense combination that 
provides the most potent suppression of the target mRNA, and several rules have been 
established to give > 90% gene expression inhibition. RNAi technology can be directed 
against cancer and various diseases using a variety of genetic therapeutic strategies. The 
RNAi delivery strategies are often exploited in experimental biology to study the function of 
genes in target cells or organisms. Successful RNAi experiments are dependent on both 
siRNA design and effective delivery of siRNA duplexes into cells. 
2.1 Current challenges in RNAi in vivo 
There are several challenges that currently limit the use of RNAi in the clinic. Methods that 
overcome these are being developed and are discussed below.  
2.1.1 Design and delivery of chemically modified siRNA 
Unmodified, naked siRNA are relatively unstable in blood circulation owing to its native 
form, though they are more stable than single-stranded RNA. siRNA are rapidly degraded 
by nucleases, renal clearance, and non-specific uptake by the reticuloendothelial system 
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indicating that they have short half-lives in vivo. In order to enhance biological stability 
without affecting gene-silencing activity, chemical modifications have been introduced into 
the siRNA structure. Various chemical modifications to the backbone, base, and sugar of the 
siRNA for stability and activity against nuclease degradation have been reported. siRNA is 
an anionic macromolecule and does not readily enter cells by passive diffusion mechanisms. 
An appropriate siRNA delivery system enhances cellular uptake, protects its payload from 
enzymatic digestion and immune recognition, and improves the pharmacokinetics by 
avoiding excretion via the reticuloendothelial system and renal filtration (i.e. prolonged 
half-life in vivo) (Lorenz et al., 2004; Sioud & Sorensen, 2003; Sorensen et al., 2003). In 
addition, an appropriate delivery system localizes siRNA in the desired tissue, resulting in a 
reduction in the amount of siRNA required for efficient gene silencing in vivo, as well as 
minimized side effects. By these chemical modifications of siRNA, degradation of siRNA in 
blood and/or cells can be delayed from minutes to hours. Thus, gene-silencing activity in 
vivo can be sustained for several days in conjunction with an appropriate delivery system. 
Chemical modifications can also reduce off-target effects (Jackson et al., 2006) and alter 
thermal stability within the various critical sequence regions of the siRNA duplex for 
improved activity of siRNA (Khvorova et al., 2003; Reynolds et al., 2004; Schwarz et al., 
2003). Also, this kind of backbone modification enhances the resistance of siRNA to 
enzymatic hydrolysis, immunogenicity and toxicology  
2.1.2 Local versus systemic siRNA delivery 
To achieve RNAi via siRNA delivery in vivo, it is critical for siRNA to be efficiently located 
in desired tissues/cells. The types of target tissues and cells dictate the optimum 
administration routes of local versus systemic delivery. For example, siRNA can be directly 
applied to the eye, skin or muscle via local delivery, whereas systemic siRNA delivery is the 
only way to reach metastatic and hematological cancer cells (Shim & Kwon, 2010). Recent 
study has indicated systemic siRNA delivery imposes several additional barriers compared 
with local delivery. Local delivery offers several advantages and makes achieving efficient 
RNAi over systemic delivery, such as low effective doses, simple formulation (e.g. no 
targeting moieties), low risk of inducing systemic side effects and facilitated site-specific 
delivery (Dykxhoorn et al., 2006). In other word, local administration is likely to be a more 
cost-efficient strategy for siRNA delivery in vivo than systemic administration. Generally, 
naked siRNA injected into the body has a very short half life, on the order of minutes, 
limiting its usefulness (Dykxhoorn & Lieberman, 2006). However, it has been found that 
some tissues are able to uptake naked siRNA to a much higher degree than other tissues (for 
instance the eye, central nervous system, and lung) making localized delivery by direct 
injection of siRNA to these sites a possibility. For example, initial clinical trials for RNAi-
based treatment of age-related macular degeneration have exclusively used local injections 
of siRNA direct injection into the eye and central nervous system (Vives et al., 1997).   
2.1.3 Nanotechnology platforms for gene therapeutics 
The biomedical application of nanotechnology has been extensively used in drug or gene 
delivery system in the past few years. Nanotechnology is considered to be novel and 
potential technology that will have significant impact in all industrial sectors and across-the-
board applications in gene therapeutics. Nanoshells are nanoparticle beads that consist of a 
silica core coated with a thin gold shell (1 nanoparticle). Nanoparticle carriers have the 
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potential to overcome the challenges of intravascular degradation, and can provide safe and 
efficient delivery of synthetic dsRNAs. On entering the bloodstream, nanoparticles 
encounter a complex environment of plasma proteins and immune cells. Nanoparticle 
uptake by immune cells in blood circulation, such as monocytes, leukocytes, platelets and 
dendritic cells, occurs through various pathways and is facilitated by the adsorption of 
opsonins to the surface of the particle (Kim, 2007). Additionally, the application of 
nanotechnology significantly benefits clinical practice in cancer diagnosis, treatment, and 
management. Especially, nanotechnology offers a promise for the targeted delivery of 
drugs, genes, and proteins to tumor tissues and protect them from environmental factors 
which may degrade it and it typically uptake by cells with a higher efficiency (Loo et al., 
2005). 
3. Methods of siRNA delivery  
Despite quite efficient and reliable gene silencing in vitro, only limited RNAi has been 
achieved in vivo because of rapid enzymatic degradation in combination with poor cellular 
uptake of siRNA (Kirchhoff, 2008). Therefore, novel delivery systems which enable 
prolonged naked siRNA and improve accessibility to target cells via clinically feasible 
administration routes and optimized cytosolic release of siRNA after efficient cellular 
uptake, are indispensably required (Grimm & Kay, 2007). There are several methods and 
major hurdles in siRNA delivery which overcome them and are discussed below:  
3.1 Naked siRNA 
“Naked” siRNA delivery is direct injection of a saline or excipient solution containing non-
complexed siRNA sequences to a target site. Although naked siRNA was influenced by 
enzymes and rapid renal clearance, recent studies have also demonstrated the ability to 
deliver naked siRNA to target cells or tissues (for instance the eye, central nervous system, 
and lung) via local injection system delivery.  
3.2 Microinjection  
Microinjection offers a potentially powerful method for the analysis of the dynamics of 
expression because it enables real-time regulation of transient expression of multiple genes. 
Recent papers have provided a brief review of RNAi and discussion of the benefits and 
drawbacks of using long double-stranded RNA (dsRNA) into mouse oocytes and early 
embryos by microinjection and preparation and testing of constructs for transgenic RNAi 
based on long hairpin RNA expression. Furthermore, microinjection can provide a useful 
method for quantitative analysis of transient gene expression in single cells using RNAi.  
3.3 Biolistics (gene gun)  
The gene gun (also known as biolistic or bioballistic particle delivery) is the most novel 
physical transfection method. This technique is based on DNA (or RNA) become “sticky,” 
adhering to biologically inert particles such as metal atoms (usually tungsten or gold), and 
then are accelerated to high velocity to get into target tissues or cells (Klein et al., 1992; 
Uchida et al., 2009). This approach allows DNA (or RNA) to penetrate directly through cell 
membranes into the cytoplasm or even the nucleus, and to bypass the endosomes, thus 
avoiding enzymatic degradation. Gene guns are so far mostly applied for plant cells. 
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However, there is much potential use in animals and humans as well. This technology was 
useful to transfection of cells and assessed by analyzing gene expression. Optimal 
transfection conditions were determined to be between 75 and 100 psi of helium pressure, 
1.0 to 1.6 μm gold particle size and 0.5 mg of gold particle amount with a loading ratio of 4 
μg DNA/mg gold particles (Uchida et al., 2009). These findings will be useful and suitable 
in the design of gene gun device, and bring further improvements to the in vivo transfection 
studies including gene therapy and vaccination. 
3.4 Liposome 
To increase the half-life of siRNA in vivo it can be encapsulated within liposomes or 
complex with cationic lipid to form siRNA-laden nanoparticles. Liposome are vesicles 
composed of phospholipids bilayer membranes that can enclose various substances, 
including DNA, siRNA, peptides, proteins, aptmers, chemicals, and drugs. Research on 
using liposomes to encapsulate and deliver chemotherapeutics has been performed since the 
late 1970s, and in the early 1980s they were extensively studied as potential vectors for gene 
therapy (Felgner et al., 1987). Recently, liposomes containing siRNA were modified with a 
peptide that targeted MCF-7 breast cancer cells, and were shown to effectively silence the 
expression of the PDMR14 gene that plays a role in breast cancer carcinogenesis, with 
minimal uptake and silencing effect in other non-cancerous cells (Bedi et al., 2011). Cationic 
liposomes can condense nucleic acids into a cationic particle when mixed together. This 
cationic lipid/nucleic acids complex (also called lipoplex) can protect nucleic acids from 
enzymatic degradation and deliver nucleic acids into cells by interacting with negatively 
charged cell membrane. Cationic liposomes have also been applied with substantial success 
for the in vitro as well as in vivo delivery of siRNA. Studies have been reported utilizing the 
advantage RNAi technology in vivo is successful knockdown of ApoB in nonhuman 
primates by systemically delivered siRNA in stable nucleic acid-lipid particles. The siRNA-
lipid complexes showed significantly enhanced cellular internalization and endosomal 
escape of siRNA. Thus, the resulting ApoB siRNA-carrying liposome were stable during 
circulation in vivo after i.v. injection and reduced ApoB expression and serum cholesterol 
levels (Zimmermann et al., 2006).  
3.5 Protein transduction domain-mediated siRNA  
CPPs, also referred protein transduction domains (PTD) are short cationic peptide chains 
with a maximum of 30 amino acids. CPPs are able to penetrate biological membranes, to 
trigger the movement of various biomolecules across cell membranes into the cytoplasm 
and to improve their intracellular routing thereby facilitating interactions with the target. 
CPPs have been reported to deliver a wide variety of cargo (e.g. plasmid DNA, 
oligonucleotide, siRNA, protein, peptide, liposome, nanoparticle…), they are rapidly taken 
up into primary cells and most tissues by macropinocytosis in clinical trials. Most cellular 
uptake studies of PTD in the literature based on fluorescence microscopy of fixed cells and 
flow cytometry analysis report that internalization of PTD (Suzuki et al., 2002; Torchilin et 
al., 2001). As RNAi is one of the most promising strategies for gene therapy, further 
advances in CPP-based RNA delivery are expected in the near future. 
3.6 Cationic polymers and polypeptide 
Nucleic acids such as siRNA are easily complexed with synthetic cationic polymers e.g., 
polyethylenimine (PEI), biodegradable cationic polysaccharide (e.g. chitosan) and cationic 
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polypeptides (e.g. atelocollagen, poly-L-lysine and protamine), via attractive electrostatic 
interactions. Polymer reduction can also allow for the release of nucleic acids into the 
cytoplasm. The use of reducible polymers and peptides is therefore a rapidly emerging 
strategy for enhanced transfection efficiency and cytoplasm-sensitive gene delivery. Various 
reduction-sensitive cationic polymers have been developed for gene delivery because they 
are highly stable in physiological conditions and rapidly reduced in the cytosol. For 
example, i.v. injection of siRNA-atelocollagen complexes silenced luciferase expression in 
germ cell tumor xenografted in mice and inhibited tumor growth (Minakuchi et al., 2004). In 
another study, the vascular endothelial growth factor (VEGF) siRNA-atelocollagen 
complexes successfully suppressed the secretion and expression of VEGF in human prostate 
PC-3 carcinoma cells, leading to the potent suppression of tumor growth in its xenograft 
model. This result clearly demonstrated that a novel VEGF blockade system by RNAi is 
valid as a therapeutic (Takei et al., 2004). Previous papers have demonstrated 
overexpression of RhoA in cancer indicates a poor prognosis, because of increased tumor 
cell proliferation and tumor angiogenesis. Furthermore, Pille´ et al showed that anti-RhoA 
siRNA inhibited aggressive breast cancer more effectively than conventional blockers of 
Rho-mediated signaling pathways. Likewise, the study has also demonstrated that 
intravenous administration of chitosan-RhoA siRNA complexes resulted in effective gene 
silencing in subcutaneously implanted breast cancer cells in nude mice (Pille et al., 2006). 
Tumor necrosis factor expression in systemic macrophages was silenced in mice after i.p. 
administration of chitosan⁄siRNA complexes, thus downregulating systemic and local 
inflammation (Howard et al., 2009). 
3.6.1 Polyethylenimine 
Polyethylenimine (PEI) is a synthetic polymer that can be either linear or branched, PEI is a 
well-known cationic polymer utilized as a non-viral vector because of its strong binding 
affinities to nucleic acids and proton buffering effect. In particular, 25 kDa PEI has been 
widely used in gene delivery. PEI with a high percentage of free amine groups which are 
positively charged and it is one of the most popularly investigated synthetic cationic 
polymers for nucleic acid delivery in vitro and in vivo. Paper has demonstrated that the 
noncovalent complexation of synthetic c-erbB2 ⁄ neu (HER-2) siRNA with low molecular 
weight polyethylenimine efficiently stabilizes siRNAs and delivers siRNAs into tumor cells 
via i.p. administration and results in a remarkable reduction of tumor growth, where where 
they display full bioactivity at completely nontoxic concentrations (Urban-Klein et al., 2005).  
Angiogenesis is the formation of new blood vessels from preexisting microvessels. In 
particular, tumor growth and metastasis were found to be dependent on angiogenesis. Thus, 
anti-angiogenic therapy has become an important route for cancer treatment (Cvetkovic et 
al., 2001; Lu et al., 2005). Likewise, a recent clinical trial examined the delivery of siRNA-
laden polyethylenimine- based polymer modified with a targeting VEGF has been injected 
directly into subcutaneous tumors, and the silencing of VEGF and subsequent diminishment 
tumor growth was confirmed (Kim et al., 2008). For inhibition of VEGF expression, several 
gene therapeutic approaches using antisense oligonucleotide, ribozyme, and siRNA have 
been suggested as potential strategies for anti-cancer therapy (Lu et al., 2005; Rhee & Hoff, 
2005; Takei et al., 2001). In another study, polyethylenimine-conjugated siRNA against 
secreted growth factor pleiotrophin (PTN) reduced tumor growth and cell proliferation 
without a measurable induction of siRNA-mediated immunostimulation after intracerebral 
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or subcutaneous administration in an orthotopic glioblastoma nude mice model (Grzelinski 
et al., 2006). Overall, polyethylenimine seems to be a promising nonviral platform for siRNA 
delivery in vitro.   
3.6.2 Chitosan 
Chitosan, a linear and cationic polysaccharide composed of randomly distributed β-(1-4)-
linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit), is 
one of such biodegradable polymers, which has been extensively exploited for the 
preparation of nanoparticles for oral controlled delivery of several therapeutic agents. In 
recent years, the area of focus has shifted from chitosan to chitosan derivatized polymers, 
such as trimethylchitosan for the application of non-viral and non-toxic gene delivery. Paper 
has been shown quaternised chitosan transfect breast cancer cells; with the most efficient at 
gene delivery. In addition, chitosan's properties also allow it to be used in trans-dermal drug 
delivery. 
3.6.3 Polypeptides  
Polypeptides, such as poly-L-lysine and protamine, have also commonly been used to 
deliver siRNA. Poly-L-lysine (PLL) is a cationic polypeptide with the amino acid lysine as 
the repeating unit (Watanabe et al., 2009). PLL can be synthesized using various strategies 
leading to PLLs with different molecular weights (typically 1 kDa up to > 300 kDa), in linear 
conformation or as highly branched polypeptide (Garnett, 1999; Yoshida & Nagasawa, 
2003). Also, protamine, a natural arginine-rich cationic polypeptide, condenses negatively 
charged nucleic acids and has been used as an efficient gene-delivery carrier (Vangasseri et 
al., 2005). Recent studies have investigated the low molecular mass protamine 
(LMWP)/VEGFsiRNA complex treatment, which possessed membrane translocating 
potency, the peptide could carry and localize siRNA inside tumors via i.p. administration 
and successfully inhibited the expression of VEGF, thereby suppressed the growth of 
hepatocarcinoma tumors in tumor-bearing mice (Choi et al., 2010). The data in this study 
clearly demonstrate that cell penetrating peptide-based systems not only enhance cellular 
uptake of siRNA, but also facilitate the suppression of VEGF expression without causing 
detectable systemic side effects. Furthermore, The LMWP is a potent transducible cell 
penetrating carrier for gene products including siRNA, and that potent growth inhibitory 
effects of the LMWP / VEGFsiRNA complex in vitro and in vivo. In addition, previous 
paper has also developed an efficient and low immunostimulatory nanoparticle formulation 
[liposomes-protamine-hyaluronic acid nanoparticle (LPH-NP)] for systemically delivering 
siRNA into the tumor (Chono et al., 2008). Overall, we expected that LMWP peptide and 
protamine could be used as a tool for siRNA delivery and may be applicable in an anti-
angiogenic regulator to treat cancer in the future.  
3.7 Electroporation  
Electroporation, or electropermeabilization, is a popular in vitro technique for introducing 
siRNA or plasmid DNA into living cells. The application of electric pulses opens pores in 
the cell plasma membrane through which siRNA or DNA can pass and directly enter into 
the cytoplasm. Then, the pores close again and the DNA is trapped within the cell 
(Neumann et al., 1982). So, it is a significant increase in the electrical conductivity and 
permeability of the cell plasma membrane caused by an externally applied electrical field, 
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and is usually used in molecular biology as a way of introducing some substance into a cell, 
such as loading it with a molecular probe, a drug that can change the cell's function, a piece 
of coding DNA or siRNA. Many research techniques in molecular biology require a foreign 
gene or protein material to be inserted into a host cell. Since the phospholipid bilayer of the 
plasma membrane has a hydrophilic exterior and a hydrophobic interior, any polar 
molecules, including DNA and protein, are unable to freely pass through the membrane 
(Hou, 2001). Electroporation is a dynamic phenomenon that depends on the local 
transmembrane voltage at each point on the cell membrane. It is generally accepted that for 
a given pulse duration and shape, a specific transmembrane voltage threshold exists for the 
manifestation of the electroporation phenomenon (from 0.5 V to 1 V). This leads to the 
definition of an electric field magnitude threshold for electroporation (Eth). That is, only the 
cells within areas where E≧Eth are electroporated. If a second threshold (Eir) is reached or 
surpassed, electroporation will compromise the viability of the cells, i.e., irreversible 
electroporation. This procedure is also highly efficient for the introduction of foreign genes 
in tissue culture cells, especially mammalian cells. For example, it is used in the process of 
producing knockout mice, as well as in tumor treatment, gene therapy, and cell-based 
therapy.  
3.8 Calcium phosphate precipitation  
A number of non-viral vectors have been explored till now. Some of these include cationic 
lipids, cationic polymers, peptides, other synthetic vectors, and precipitated calcium 
phosphate. Among these, the technique of calcium phosphate co-precipitation for in vitro 
transfection is used as a routine laboratory procedure. Calcium phosphate (CaP) is a well 
used non-viral vector for in vitro transfection of a wide variety of mammalian cells with 
little toxicity (Sokolova & Epple, 2008). Especially, DNA or siRNA-calcium phosphate 
coprecipitates have been used for many years as an efficient method to introduce genetic 
material in to cells, and the calcium phosphate particles have attracted much attention in 
gene therapy. Nucleic acids alone cannot penetrate the cell membrane, therefore special 
carriers like cationic polymers or inorganic nanoparticles are required. Single-shell and 
multi-shell calcium phosphate nanoparticles were prepared and functionalized with DNA 
and siRNA. The delivery activity is probably related to the fact that CaP rapidly dissolves in 
the acidic pH (Bisht et al., 2005). Endocytosed CaP is expected to deassemble in the 
endosomes and release its cargo into the cytoplasm. Many investigators have attempted to 
improve the manufacture of the CaP precipitate with limited success (Olton et al., 2007). In 
past study has reported that calcium ions play an important role in endosomal escape, 
cytosolic stability and enhanced nuclear uptake of siRNA through nuclear pore complexes. 
The siRNA encapsulated inside the nanoparticle is protected from the external RNase 
environment and could be used safely to transfer the encapsulated siRNA under in vivo 
conditions (Maitra, 2005). Thus, CaP precipitation is a dynamic and reversible process, and 
it can have multiple applications in gene function, regulation, and therapy and achieve its 
full potential in transfectional mammalian cells. 
4. Application of RNAi  
4.1 Clinical trials 
There are many RNAi therapeutics approved by the U. S. Food and Drug Administration in 
various diseases in clinical trials (Table 1). Two ex vivo studies provided by City of Hope 
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Medical Center have designed for treating HIV infection through targeting on HIV tat and 
rev. IV transfer of in vivo lentiviral infected cells was used to treat patients with HIV 
infection. The expression of shRNA of tat and rev can knockdown the viral mRNA in T 
lymphocytes. 
Four of these therapeutics for treating solid tumors are CALAA-01, siG12D LODER, ALN-
VSP02, and Atu027. CALAA-01 provided by Calando Pharmaceuticals is a targeted 
therapeutic designed to inhibit tumor growth and/or reduce tumor size. It consists of a 
duplex siRNA to repress the expression of M2 subunit of ribonucleotide reductase. Another 
component AD-PEG-Tf combines the siRNA molecule with the transferrin receptor of the 
tumor cell surface to target the solid tumors. The majority of pancreatic ductal 
adenocarcinomas involve mutations in the KRAS oncogene, especially most common in 
G12D mutation. siG12D LODER provided by Silenseed Ltd is designed to inhibit oncogene 
KRas G12D mutation specifically. ALN-VSP02 provided by Alnylam Pharmaceuticals and 
Atu027 provided by Silence Therapeutics AG are both designed to inhibit growth and 
survival of cancer cells by tumor angiogenesis. ALN-VSP02 is a systemically delivered 
therapeutic packaged in Tekmira’s SNALP delivery formulation and containing two siRNAs 
designed to target VEGF and kinesin spindle protein (KSP), also known as eglin 5 (Eg5), 
which disrupts cell division and induces apoptosis. In addition, in vitro studies revealed 
that Atu027-mediated inhibition of protein kinase N3 function in primary endothelial cells 
impaired tube formation on extracellular matrix and cell migration (Aleku et al., 2008). 
There are five RNAi therapeutics approved by the U.S. FDA to treat ocular diseases, four 
designed in targeting VEGF and its receptor and one in caspase 2. Bevasiranib provided by 
Opko Health, Inc. involves in three clinical trials in treating macular edema and 
degeneration by 2-dT-modified siRNA on 3’ end. Similarly, Allergan designed a siRNA 
targeting on VEGF receptor 1 to treat the same disease. In addition, a synthetic siRNA 
provided by Quark Pharmaceuticals, QPI-1007, inhibits expression of caspase 2 in retinal 
ganglion cells to prevent glaucoma, non-arteritic anterior ischemic optic neuropathy 
(NAION), and other ocular diseases.  
There are two trials approved by FDA in treating kidney diseases using the same drug, 
I5NP, containing siRNA for p53, which arrests cell cycle progression and promotes cellular 
apoptosis. I5NP is provided by Quark Pharmaceuticals and designed to knockdown p53 to 
prevent cellular apoptosis of kidney in treating acute renal failure as well as in 
delayed graft function during kidney transplantation. Pachyonychia congenita is a rare 
keratin mutant disease, which affects the nails, skin, oral mucosae, larynx, hair and teeth. 
The majority of pachyonychia congenita involves mutations in the keratin gene, such as K6a, 
K6b, K16 or K17. A clinical trial using siRNA was applied by Pachyonychia Congenita 
Project. And, the siRNA was developed and provided by a small company, TransDerm, Inc., 
to inhibit the expression of the keratin K6a N171K mutation specifically. 
4.2 Other approaches 
4.2.1 Host protein screening and controlling of viral infection 
Large siRNA libraries are constructed to knockdown all proteins known to be encoded by 
the human and mammalian genomes. Therefore, using siRNA library screening to identify 
the interacting proteins related to viral infection is a new approach. Several studies were 
carried out to screen the host factors of viruses, such as HIV, West Nile virus, Dengue virus, 
hepatitis C virus and influenza (Hirsch, 2010). 
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Disease Sponsor Product Target gene 
Target 
cell/tissue 
Type of 
RNAi 
Status 
HIV 
City of Hope 
Medical Center
rHIV7-shI-
TAR-
CCR5RZ-
transduced 
autologous 
HPCs 
HIV tat and 
rev 
CD34+ Cells 
Lentivirus 
(in vitro) 
Active, not 
recruiting 
HIV 
City of Hope 
Medical Center
pHIV7-shI-
TAR-
CCR5RZ 
treated CD4 
cells 
HIV tat and 
rev 
T 
lymphocytes
Lentivirus 
(in vitro) 
Phase 0 , 
terminated 
Solid tumors 
Calando 
Pharmaceuti-
cals 
CALAA-01
M2 subunit of 
ribonucleotide 
reductase 
Solid tumors
Nanocom-
plex, 
synthetic 
siRNA 
Phase I , 
recruiting 
Pancreatic 
cancer 
Silenseed Ltd 
siG12D 
LODER 
KRAS 
oncogene 
G12D 
mutation 
Pancreatic 
ductal 
adenocarci-
noma 
Polymeric 
matrix, 
synthetic 
siRNA 
Phase I , 
recruiting 
Solid tumors 
Alnylam 
Pharmaceuti-
cals 
ALN-VSP02
Vascular 
endothelial 
growth factor 
(VEGF) and 
kinesin 
spindle 
protein (KSP)
Solid tumors, 
liver 
SNALP 
particle, 
synthetic 
siRNA 
Phase I , 
recruiting 
Advanced 
solid tumors 
Silence 
Therapeutics 
AG 
Atu027 
Protein kinase 
N3 
Advanced 
solid tumors 
Liposome, 
2'-O-methyl 
modified 
synthetic 
siRNA 
Phase I , 
recruiting 
Age-related 
macular 
degeneration 
Allergan AGN211745
VEGF 
receptor-1 
Macula cells 
(retina) 
 
Chemically 
modified 
siRNA 
Phase II , 
completed 
Diabetic 
macular 
edema 
Opko Health, 
Inc. 
Bevasiranib VEGF 
Retinal 
vasculature 
3'-2 dT-
capped 
synthetic 
siRNA 
Phase II, 
completed 
Age-related 
macular 
degeneration 
Opko Health, 
Inc. 
Bevasiranib VEGF 
Retinal 
vasculature 
3' 2 dT-
capped 
synthetic 
siRNA 
Phase III, 
withdrawn 
Macular 
degeneration 
Opko Health, 
Inc. 
Bevasiranib VEGF 
Retinal 
vasculature 
3' 2 dT-
capped 
synthetic 
siRNA 
Phase II, 
completed 
Optic 
neuropathy 
Quark 
Pharmaceuti-
cals 
QPI-1007 Caspase 2 
Retinal 
ganglion cells
Synthetic 
siRNA 
Phase I , 
recruiting 
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Disease Sponsor Product Target gene 
Target 
cell/tissue 
Type of 
RNAi 
Status 
Pachyonychia 
congenita 
Pachyonychia 
Congenita 
Project 
(TransDerm, 
Inc.) 
TD101 
Keratin K6a 
N171K 
mutation 
Skin  
Phase I , 
completed 
Hyperchole- 
sterolemia 
Tekmira 
Pharmaceuti-
cals Corporation
PRO-040201 ApoB  
SNALP 
particle, 
synthetic 
siRNA 
Phase I , 
terminated 
Acute renal 
failure 
Quark 
Pharmaceuti-
cals 
I5NP P53 Kidney 
Synthetic 
siRNA 
Phase I , 
completed 
Delayed graft 
function 
Quark 
Pharmaceuti-
cals 
I5NP P53 Kidney 
Synthetic 
siRNA 
Phase I/II , 
recruiting 
Table 1. RNAi theraputics in clinical trials. (From the U.S. National Library of Medicine, A 
service of the U.S. National Institute of Health) 
Human immunodeficiency virus type 1 (HIV-1) belongs to the family of retroviruses, infects 
human CD4+ lymphocytes and causes an indolent-type of infection and terminally ended to 
acquired immunodeficiency syndrome (Alimonti et al., 2003; Guadalupe et al., 2003). 
Because RNAi provides a strong justification to become a novel but remarkable therapeutic 
strategy in inhibiting gene expression, including viral mRNAs, many scientists participate in 
developing new methods using RNAi to treat HIV replication (Berkhout, 2009; Soejitno et 
al., 2003). In addition to HIV, RNAi is also used in controlling infection of several viruses, 
such as hepatitis B, hepatitis C, influenza, parainfluenza, CVB3, JEV, HSV2, RSV, PIV, SARS, 
foot-and-mouth disease and West Nile viruses (Chen et al., 2008; Khaliq et al., 2010; López-
Fraga etal., 2008). 
4.2.2 Neurodegenerative diseases 
Neurodegenerative diseases are characterized by incorrect expression or selective 
dysfunction of proteins and eventual death of distinct subpopulations of neurons occurred 
in the central nervous system, such as Alzheimer’s, Huntington’s and Parkinson’s diseases. 
They are solely caused by the inheritance of genetic mutations and several strategies using 
RNAi to target the specific mutant genes to treat these diseases in cellular and animal 
models were developed (Boudreau & Davidson, 2010; Maxwell, 2009). In contrast to these 
diseases, prion disease is caused by the conversion of a highly conserved prion protein 
across species, PrPc, into a partially protease-resistant isoform, PrPsc, which aggregates in 
the brain and is associated with pathogenesis of a neurodegenerative disease (Prusiner, 
1991; Prusiner & DeArmond, 1991). However, the function of PrPc is not clear and its 
ablation represents no deleterious effects. Therefore, RNAi therapeutics should be useful 
strategies to target and remove normal PrPc to decrease the conversion and aggregation in 
the adult brain (Verity & Mallucci, 2010).  
4.2.3 Immune diseases 
As described above, siRNA-based therapeutics have entered clinical trials in treating many 
diseases. However, it has not been reported that siRNA can be used as an effective 
www.intechopen.com
 
Gene Therapy Using RNAi 
 
45 
alternative to the present medications, such as corticosteroids, for managing allergy in vivo 
(Suzuki et al., 2009). It has been known that CD40/CD40 ligand (CD40L) interaction 
enhances Th2 cytokine production. Suzuki and colleagues have developed siRNA-based 
therapeutics to inhibit CD40 expression and found that decreased CD40 levels attenuated 
allergy through inhibition of functions of dendritic and B cells and generation of regulatory 
T cells (Suzuki et al., 2009). Bronchial asthma is a common inflammatory disease associated 
with allergy and activation of T helper type 2 cells, which secret cytokines to mediate local 
or systemic inflammation. One of inflammatory factors, interleukin 13 has been identified as 
a major driver of asthma pathology. Walker et al. used STAT6 siRNA to inhibit its 
expression and therefore found decreased downstream IL-13 as well as IL-4 and CCL26 
protein expression in lung epithelial cells (Walker et al., 2009). The main inflammatory 
cytokines IL-1 and TNF- are considered as potential targets for rheumatic diseases therapy. 
NF-κB is one of the key transcription factors associated with inflammatory pathway. siRNA 
specific for NF-κB p65 subunit is used in animal models to treat rheumatic diseases. It has 
been found that NF-κB downstream signaling molecules, such as cyclooxygenase-2, nitric 
oxide synthase-2, and matrix metalloproteinase-9 (de França et al., 2010; Lianxu et al., 2006). 
4.2.4 Cancer gene therapies 
Numerous scientists have designed shRNA or siRNAs in various cancer cell and animal 
models to develop the applications of RNAi in cancer therapeutics. He and colleagues have 
discussed genes associated with tumor growth and metastasis as well as adjuvant therapies 
for tumor radiation and chemotherapy (He et al., 2009). In addition to genes discussed by 
He et al., cyclooxygenase-2 (COX-2) is also a candidate for RNAi suppression, because it 
involves in tumor angiogenesis. Several in vitro studies have revealed that overexpression 
of COX-2 inhibits cellular apoptosis and promotes tumor angiogenesis. Therefore, COX-2 
may play an important role in developing new vasculature, which involves in tumor growth 
and metastasis (DuBios et al., 1998; Liu et al., 2001; Tsujii et al., 1998; Wang & DuBois, 2010). 
Similar to identifying the interacting proteins related to viral infection (Hirsch, 2010), RNAi 
also paves the way for large scale loss-of-function genetic screens in mammalian cells to 
understand the cancer biology (Ashworth & Bernards, 2010). It also provides a novel and 
viable tool help in the identification of targets for treating cancer diseases and of those 
patients that are respond to a given therapy (Ashworth & Bernards, 2010; Micklem & 
Lorens, 2007; Nijwening & Beijersbergen, 2010). 
5. Conclusion 
RNA interference offers great promise for treating various disease states or helping to repair 
damaged tissue. Especially, initially in vivo studies demonstrated effective tumor 
suppression in nude mice by chemically synthesized siRNAs. More recently, many 
researchers have used non-viral or viral vectors for transcription of siRNAs / shRNAs in 
vitro and in vivo. RNAi technology has quickly been advanced from research discovery to 
clinical trials as effective gene silencing and therapeutic strategy since its discovery in 1998. 
Nevertheless, viral siRNA delivery raises several safety and preparation concerns such as 
immune responses and limited large-scale production. Non-viral siRNA have been 
developed to enhance transfection efficiency, minimize cytotoxicity and improve the 
bioactivities of nucleic acids, and then had competent in tackling the barriers in siRNA 
circulation, permeation into target tissues (ex. eye, central nervous system, muscle, and 
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lung) specific binding to target cells and optimized intracellular trafficking. Recent advances 
clearly indicate that interdisciplinary approaches using biology, chemistry and engineering 
play crucial roles in achieving efficient and targeted siRNA delivery in vivo. In certain 
tissues, it has been demonstrated that a simple injection of naked siRNA will silence gene 
expression specifically in that tissue. In addition, to achieve local gene silencing in other 
tissues, a variety of approaches have been pursued to help stabilize the siRNA and to 
encourage cellular uptake by administration to the site of interest; they include chemical 
modification of the siRNA or complexation within liposomes or polymers to form 
nanoparticles. Overall, the field of siRNA delivery has been very focused on the use of 
nanoparticles. 
The application of nanoparticles in medicine is an emerging field of nanobiotechnology 
(Kim, 2007). As a result of their small size, nanoparticles can penetrate the cell wall and 
deliver drugs or biomolecules into living systems, usually for a therapeutic purpose. Many 
different kinds of nanoparticles are known, many have been tested on biosystems, and some 
approaches have made it into clinical trials (Chen et al., 2010; Strong & West, 2011). Thus, 
this multifunctional, unique nanoparticulate carrier has the potential to detect diseases, 
deliver medications, and monitor the ability to change the current scenario of various 
diseases research and diagnosis in real time. Despite all this, the discovery and 
characterization of RNAi is not only as a powerful molecular biological tool to suppress the 
expression of a target gene, but also as an emerging therapeutic strategy to silence disease 
genes (Harrington, 2001). This work is not intended to give a comprehensive review of the 
antisense world, but rather to focus on what we know about the mechanism and function of 
RNAi, and how this molecule can best be applied as a therapy against various diseases.  
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